Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Inthepezon Jan 16, 2021 5:59pm
301 Views
Post# 32314131

RE:RE:More recent validation

RE:RE:More recent validationIts not that perplexing man. The company needs to have actual revenue not reports of ‘potential’ revenue. Execution is everything. I believe in this company but it’s not going to move till we get some real news.

Its easy to dream and project numbers. It’s another to be patient and execute. Dan messed up a number of times which was listed by myself and several other people. That’s why we’re stagnate.

Hopefully (and I hate using that word in investing), Stauffer and Haut can get us to the next level, so we can get that uncertain partnership or that ‘hypothetical’ buyout payday we we’re dreaming of. 

I honestly think you can take out your money, make a few plays elsewhere, and then re-enter ATE with the extra gains well past this quarter. Why? Again the science not the management. Just don’t be dumpster like duster and tell us BS small fish penny flips lol

jmo
<< Previous
Bullboard Posts
Next >>